The firm it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series.
The company missed the analysts' average estimates on the top and bottom lines, but it raised its full-year 2019 revenue guidance.
The companies will build clinical-genomic datasets to serve medical practitioners at the point of care as well as inform drug development.
Buoyed by a 26 percent increase in test volume, the firm's revenues were $1.2 million for the quarter, compared to $822,000 last year.
Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
Researchers developed a microfluidic device that combines antibody-based cell capture and disulfide cleavage for downstream microRNA detection.
Kary Mullis, who won the Nobel Prize in Chemistry in 1993 for his work on PCR has died at 74, South Carolina's The State reports.
More than two dozen University of California researchers are taking a break from their positions on the editorial boards of Elsevier journals, according to ScienceInsider.
A new California law would outlaw the sale of gene-editing kits without a label saying not to use it on yourself, Technology Review reports.
In PLOS this week: researchers uncover genetic variants and gene-tissue-phenotype associations contributing to lipid traits in Hispanic populations, role of PAX5 in human B-lineage leukemia, and more.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.